rss
Br J Ophthalmol 2007;91:743-745 doi:10.1136/bjo.2006.107466
  • Clinical science
    • Scientific reports

Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa

  1. Gerald A Fishman,
  2. Marsha A Apushkin
  1. Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, USA
  1. Correspondence to: Dr G A Fishman University of Illinois at Chicago Eye Center, University of Illinois at Chicago (M/C 648), 1855 W Taylor Street, Chicago, IL 60612, USA; gerafish{at}uic.edu
  • Accepted 8 December 2006
  • Published Online First 10 January 2007

Abstract

Aim: To determine the value of a topical carbonic anhydrase inhibitor for extended treatment of cystoid macular oedema (CME) in patients with retinitis pigmentosa (RP).

Method: Eight patients with RP and foveal cystic-appearing lesions observed on fundus examination and by optical coherence tomography (OCT) testing were treated with a topical form of carbonic anhydrase inhibitor.

Results: Foveal cystic-like spaces were documented by OCT testing in all eight patients before treatment. All patients had a significant reduction in their foveal thickness (FT) and foveal zone thickness (FZT) in at least one eye after using 2% dorzolamide three times a day for 1 or 2 months. Six patients had an improvement in both eyes. After an additional 6–13 months of the same treatment regimen, out of six patients who had a sustained reduction in FT and FZT in at least one eye, four had this reduction in both eyes. While they were still taking Trusopt, a recurrence (rebound) of CME in both eyes was observed in two patients, whereas one patient had a sustained improvement in one eye and rebound of CME in the other eye. Out of 8 patients, 3 showed an improvement in their visual acuity by ≥7 letters, in at least one eye, on Snellen acuity charts, which was determined as clinically significant.

Conclusion: Results from this study suggest that patients with RP could potentially sustain a beneficial effect from continued treatment with a topical form of carbonic anhydrase inhibitor.

Footnotes

  • Published Online First 10 January 2007

  • Funding: This study was supported by funds from the Foundation Fighting Blindness, Owings Mills, Maryland; The Grant Healthcare Foundation, Chicago, Illinois; NEI core grant EY01792, Bethesda, Maryland; and an unrestricted departmental grant from Research to Prevent Blindness, New York, New York, USA.

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2006.107466v1
    2. 91/6/743 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.